Hafnium oxide nanoparticles and radiotherapy for solid tumors: a promising new treatment strategy

ESTRO, Barcelona, Spain · 2018, Le Tourneau C. et al.


Le Tourneau C.1, Le Pechoux C.2, Kantor G.3, Carrere S.4, Bonvalot S.1, Le Prise E.5, Nguyen F.2, Baumann A. S.6, Vendrely V.7, Bronowicki J. P.8, Moreno-Garcia V.9, Delannes M.10, Thariat J.11, Papai Z.12, Ruthowski P.13, Tiangco B.14, Rastrelli M.15, Agoston P.16, Sunyach M.P.17, Rubi Li K.18, Mervoyer A.19, Sy-Ortin T.20, Hong A.21, Anghel R.22, Gronchi A.23
1 – Institut Curie, Oncology, Paris, France
2 – Institut Gustave Roussy, Oncology, Villejuif, France
3 – Institut Bergonié, Oncology, Bordeaux, France
4 – ICM, Oncology, Montpellier, France
5 – Eugène Marquis, Oncology, Rennes, France
6 – Cancérologie de Lorraine, Oncology, Nancy, France
7 – Hôpital du Haut-Lévêque, Oncology, Bordeaux, France
8 – Hôpitaux de Brabois CHU Nancy, Oncology, Nancy, France
9 – START Madrid, Oncology, Madrid, Spain
10 – Claudius Regaud, Oncology, Toulouse, France
11 – Antoine Lacassagne, Oncology, Nice, France
12 – Medical Centre- Hungarian Defence Forces, Oncology, Budapest, Hungary
13 – Maria Sklodowska-Curie Institute – Oncology Center, Warsaw, Poland
14 – The Medical City, Oncology, Pasig City, Philippines
15 – Veneto institute of oncology, Padua Italy
16 – Országos Onkológiai Intézet, Oncology, Budapest, Hungary
17 – Centre Léon Bérard, Oncology, Lyon, France
18 – St. Luke’s Medical Center, Oncology, Quezon City, Philippines
19 – Centre Rene Gauducheau- CLCC Nantes Atlantique, Oncology, St Herblain, France
20 – University of Santo Thomas, Oncology, Manila, Philippines
21 – Chris O’Brien Lifehouse, Oncology, Sidney, Australia
22 – Institutul Oncologic Bucuresti- “Prof. Dr. Alexandru Trestioreanu”, Oncology, Bucharest, Romania
23 – Fondazione IRCCS Istituto Nazionale dei Tumori, Oncology, Milan, Italy


With recent advances in radiation delivery techniques, an increasing number of cancer patients undergo radiotherapy. However, due to the non-targeted nature of radiotherapy, doses are limited by potential toxicity to surrounding normal tissue. Thus, a major challenge remains to develop new strategies to improve the tumor selectivity of radiation therapy. Nanobiotix has developed NBTXR3 – a hafnium oxide nanoparticle that can enter tumor cells and deposit high levels of energy in cells when exposed to ionizing radiation thereby increasing tumor-specific physical killing through DNA damage/cell destruction and enhancing the intratumoral immune profile.

At 2018 ESTRO, an overview of NBTXR3 was presented, describing its role in current 7 clinical trials.

By continuing to use the site, you agree to the use of cookies.En poursuivant votre navigation sur ce site, vous acceptez l’utilisation de cookies. More information.En savoir plus.

The cookie settings on this website are set to “allow cookies” to give you the possibility to switch between languages in a way that this will not interfere with page navigation. If you continue to use this website without changing your cookie settings or you click “Accept” below then you are consenting to this.Par défaut, les paramètres de ce site autorisent les cookies pour vous permettre notamment de naviguer entre les différentes langues disponibles. Nous utilisons des cookies pour vous proposer un site internet facile d'utilisation, sécurisé et fonctionnel. Si vous les autorisez également, cliquez sur « Accepter » ou poursuivez simplement votre navigation.